View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry

Blog

IO360° Speaker Dr. Edith Perez on The People Behind the Data


  • December 10, 2015

  • Conference Forum speaker Dr. Edith Perez, VP and Head of BioOncology, US Medical Affairs for Genentech recently wrote a blog piece that discusses the value of patients and how their involvement in clinical trials can help further research and development.

    Edith_Perez-1

    Dr. Edith Perez at Immuno-Oncology 360°


    The p
    eople behind the data – they are the true heroes helping us find the next cancer breakthrough.”

    – Edith Perez, MD, Genentech

    Dr. Perez joined us last year at our inaugural Immuno-Oncology 360° program to discuss clinical trial design and management for cancer immunotherapies.

    At that program, we featured a patient, Jamie Goldfarb, who had stage 4 melanoma and is now cancer free as a result of participating in an immunotherapy clinical trial. Jamie Goldfarb is now a patient advocate and helps provide a patient’s insight in clinical development and trial design.

    This correlates to Dr. Perez’ position on patient involvement in her recent post.

    Abstract: In my work in oncology over the past 25 years, I’ve had the privilege of being involved in both research and patient care. These two fields use strikingly different approaches to achieve the same overarching goal—fighting cancer. Research is a tedious process. First, we start in the lab. We test, we tweak, and sometimes we fail before moving forward. Patient care is just the opposite. There is no room for testing or trial and error. When peoples’ lives are at risk, we do everything we can to treat the disease quickly based on what we know and make it go away.

    But ultimately, research advances do not exist without people.

    Read the full blog here: snip.ly/xIkb

    By means of the 2nd Annual Immuno-Oncology 360° program, taking place February 2-3, 2016 in NYC, we will be helping advance research and development in the cancer immunotherapy space. The program combines business and clinical development strategies with scientific updates to prepare the market for accelerating immuno-oncology (IO) clinical trials and help revolutionize the way cancer is treated.

    To learn more about the 2nd Annual Immuno-Oncology 360° conference visit: http://theconferenceforum.org/conferences/immuno-oncology-360/overview/